Sub-Community 于重元 [19/19] 劉柯俊 [85/98] 劉滄梧 [119/125] 劉界元(2003-2010) [3/3] 夏和雄(1996-2012) [26/31] 夏興國 [51/54] 姜乃榕 [82/94] 常慧如 [39/44] 張俊彥 [234/254] 張光裕 [69/79] 張憶壽 [103/106] 張文祥 [52/53] 張書銘 [89/91] 彭汪嘉康(1996-2007) [120/126] 施能耀 [37/43] 李家惠 [29/29] 李岳倫 [48/49] 林素芳 [32/32] 楊奕馨 [41/42] 江士昇 [88/90] 沈哲宏 [14/16] 洪文俊 [88/88] 莊雙恩 [82/91] 蔡坤志 [32/34] 蔡慧珍 [66/71] 蘇勇曄 [40/40] 蘇振良 [24/25] 郭靜娟 [71/76] 陳尚鴻 [45/48] 陳振陽 [72/72] 陳立宗 [443/510] 陳美霞(2002-2009) [1/1] 陳詩政 [2/2] 陳雅雯 [38/39] 黃智興 [55/55] 黃道揚 [26/26] 丁兆治(2000-2004) [5/5] 其他 [464/471] 劉敏(1996-2007) [60/62] 劉玫英(2004-2006) [2/2] 吳成文(1996-2008) [53/55] 曾思文(1997-2007) [4/4] 李冠德(1997-2004) [4/6] 林景太(1999-2007) [5/5] 楊文光(1996-1999) [21/21] 王全正(1996-2003) [4/4] 莊聲宏(1997-2004) [11/11] 詹宗晃(2000-2008) [2/2] 賴基銘(2004-2008) [41/47] 阮麗蓉(2000-2006) [6/7] 陳俊叡(2003-2007) [6/6] 馬彥英(1997-1999) [1/1] 黃奇英(2005-2007) [9/10] Siblings 分子與基因醫學研究所 [921/964] 生技與藥物研究所 [830/1008] 生醫工程與奈米醫學研究所 [1214/1334] 免疫醫學研究中心 [224/236] 神經及精神醫學研究中心 [782/804] 細胞及系統醫學研究所 [755/815] 感染症與疫苗研究所 [1541/1618] 群體健康科學研究所 [2870/3000] 國家環境醫學研究所 [1560/1591] 國家蚊媒傳染病防治研究中心 [102/104] 高齡醫學暨健康福祉研究中心 [216/224] 論壇 [2/2] 生醫資源中心 [7/7] 研究生培育合作學程 [188/191] 核心儀器設施中心 [9/9] 病理核心實驗室 [14/14] 實驗動物中心 [8/8] 行政管理部門 [18/18] Community Statistics 近3年內發表的文件:335(13.91%) 含全文筆數:2250(93.40%) 文件下載次數統計 下載大於0次:2250(100.00%) 下載大於100次:2250(100.00%) 檔案下載總次數:1611277(30.06%) 最後更新時間: 2024-11-28 18:37 Top Upload Loading... Top Download Loading... Recent Submissions Pathological response following neo... Registry of genetic alterations of ... Activated single nucleotide mismatc... Taiwan nationwide study of first-li... The effectiveness of virtual passpo... Special Issue "Bioinformatics ... Evaluating a natural language proce... The clinicopathological significanc... Hypoxia in drug resistance and radi... DKK1 as a chemoresistant protein mo...

Jump to a point in the index: (Choose year) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 1076-1100 of 2409. (97 Page(s) Totally) << < 39 40 41 42 43 44 45 46 47 48 > >> View [10|25|50] records per page

Date	Title	Relation
2016-05	Overexpression of regulator of G protein signaling 11 promotes cell migration and associates with advanced stages and aggressiveness of lung adenocarcinoma	Oncotarget. 2016 May;7(21):31122-31136.
2016-05	Overexpression of the PSAT1 gene in nasopharyngeal carcinoma is an indicator of poor prognosis	Journal of Cancer. 2016 May;7(9):1088-1094.
2016-05	Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine	Journal of Clinical Oncology. 2016 May;34(15, Suppl.):Meeting Abstract 4126.
2016-05	Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15740.
2016-05	Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC)	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number 4017.
2016-05	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15732.
2016-05	Efficacy of frontline antibiotics therapy in the treatment of Helicobacter pylori-negative gastric low-grade mucosa-associated lymphoid tissue lymphoma	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e19024.
2016-04-18	NF-kappaB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance	Proceedings of the National Academy of Sciences of the United States of America. 2016 Apr 18;113(18):E2526-E2535.
2016-04	Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: A nationwide cohort study	Gut. 2016 Apr;65(4):693-701.
2016-04	A 16-year experience in treating thyroglossal duct cysts with a “conservative” Sistrunk approach	European Archives of Oto-Rhino-Laryngology. 2016 Apr;273(4):1019-1025.
2016-04	Biodegradable interstitial release polymer loading a novel small molecule targeting Axl receptor tyrosine kinase and reducing brain tumour migration and invasion	Oncogene. 2016 Apr;35(17):2156-2165.
2016-04	APC haploinsufficiency coupled with p53 loss sufficiently induces mucinous cystic neoplasms and invasive pancreatic carcinoma in mice	Oncogene. 2016 Apr;35(17):2223-2234.
2016-04	Receipt of life-sustaining treatments for Taiwanese pediatric patients who died of cancer in 2001 to 2010: A retrospective cohort study	Medicine. 2016 Apr;95(16):Article number e3461.
2016-04	Vascular endothelial growth factor-C promotes EGFR-TKIs resistance and cancer stemness via SLUG of non-small cell lung cancer	Journal of Thoracic Oncology. 2016 Apr;11(4, Suppl.):S132-133.
2016-03-26	CSF2 overexpression is associated with STAT5 phosphorylation and poor prognosis in patients with urothelial carcinoma	Journal of Cancer. 2016 Mar 26;7(6):711-721.
2016-03-24	Honokiol inhibits sphere formation and xenograft growth of oral cancer side population cells accompanied with JAK/STAT signaling pathway suppression and apoptosis induction	BMC Cancer. 2016 Mar 24;16:Article number 245.
2016-03-08	EBV reactivation as a target of luteolin to repress NPC tumorigenesis	Oncotarget. 2016 Mar 8;7(14):18999-19017.
2016-03	miR-520h is crucial for DAPK2 regulation and breast cancer progression	Oncogene. 2016 Mar 3;35(9):1134-1142.
2016-03	Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer	Oncogene. 2016 May;35(12):1517-1528.
2016-03	BCAT1 overexpression is an indicator of poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder	Histopathology. 2016 Mar;68(4):520-532.
2016-03	Pancreatic tumor progression associated with CD133 overexpression: Involvement of increased TERT expression and epidermal growth factor receptor-dependent Akt activation	Pancreas. 2016 Mar;45(3):443-457.
2016-03	The clinical efficacy and cardiotoxicity of fixed-dose monthly trastuzumab in HER2-positive breast cancer: A single institutional analysis	PLoS ONE. 2016 Mar;11(3):Article number e0151112.
2016-02-10	Gastric microbiota and predicted gene functions are altered after subtotal gastrectomy in patients with gastric cancer	Scientific Reports. 2016 Feb 10;6:Article number 20701.
2016-02	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial	Lancet. 2016 Feb;387(10018):545-557.
2016-02	Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells	RNA. 2016 Feb;22(2):303-315.

Showing items 1076-1100 of 2409. (97 Page(s) Totally) << < 39 40 41 42 43 44 45 46 47 48 > >> View [10|25|50] records per page